NCT07399821 (GLOW-FISH) is a Phase 1, PHASE2 clinical trial of anti-GD2-800CW in Neuroblastoma, sponsored by Princess Maxima Center for Pediatric Oncology.

Who is sponsoring NCT07399821?

NCT07399821 is sponsored by Princess Maxima Center for Pediatric Oncology.

What drugs are being tested in NCT07399821?

Interventions in NCT07399821: anti-GD2-800CW.

What condition does NCT07399821 study?

NCT07399821 studies Neuroblastoma.

Is NCT07399821 still recruiting?

NCT07399821 is currently recruiting now. Last updated 10 February 2026.

Last reviewed 2026-02-10 · How we verify

NCT07399821: GLOW-FISH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma

Recruiting now Phase 1, PHASE2 Last updated 10 February 2026

What this trial tests

Phase 1, PHASE2 trial testing anti-GD2-800CW in Neuroblastoma in 22 participants. Currently enrolling.

Timeline

5 November 2025

Primary endpoint
1 April 2027

1 May 2027

Quick facts

Lead sponsor	Princess Maxima Center for Pediatric Oncology
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	5 November 2025
Primary completion	1 April 2027
Estimated completion	1 May 2027
Sites	1 location across Netherlands

Drugs / interventions tested

anti-GD2-800CW — full drug profile →

Conditions studied

Neuroblastoma — all drugs for Neuroblastoma →

Sponsor

Princess Maxima Center for Pediatric Oncology — full company profile →

Who can join

Adults 1 to 18, any sex, with Neuroblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a non-randomized, open label phase Ib/II dose-escalation and expansion study designed to define the recommended dose of anti-GD2-800CW in pediatric neuroblastoma patients. The aim of this imaging study is to determine a safe and effective dose of anti-GD2-800CW for intra-operative detection of neuroblastoma using NIR fluorescence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Neuroblastoma

Currently open trials in the same condition.

NCT06995872 — Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refra · Phase 1 · recruiting
NCT06942039 — Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation · EARLY_PHASE1 · recruiting
NCT07067346 — Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma · EARLY_PHASE1 · recruiting
NCT07027748 — Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or R · Phase 1 · recruiting
NCT06933394 — Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma · Phase 2 · recruiting

Other Princess Maxima Center for Pediatric Oncology trials

Trials by the same sponsor.

NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
NCT05745714 — HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Rela · Phase 1, PHASE2 · recruiting
NCT05751044 — HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relaps · Phase 1, PHASE2 · recruiting
NCT07020260 — The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell The · Phase 1, PHASE2 · not yet recruiting
NCT06485947 — Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07399821 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Princess Maxima Center for Pediatric Oncology
Last refreshed: 10 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07399821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing